Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 265.21B | 284.90B | 238.88B | 230.82B | 208.16B | 169.20B |
Gross Profit | 148.67B | 154.36B | 133.18B | 135.19B | 123.27B | 103.40B |
EBITDA | 66.41B | 75.03B | 76.75B | 77.85B | 73.64B | 64.08B |
Net Income | 41.20B | 40.48B | 45.27B | 49.03B | 63.84B | 37.82B |
Balance Sheet | ||||||
Total Assets | 577.54B | 581.74B | 490.78B | 400.64B | 345.98B | 273.12B |
Cash, Cash Equivalents and Short-Term Investments | 123.70B | 134.93B | 149.66B | 118.32B | 141.22B | 115.40B |
Total Debt | 24.47B | 24.42B | 31.78B | 10.38B | 8.30B | 9.02B |
Total Liabilities | 165.12B | 168.94B | 124.08B | 91.13B | 82.03B | 65.86B |
Stockholders Equity | 378.23B | 378.44B | 351.92B | 302.63B | 257.84B | 199.81B |
Cash Flow | ||||||
Free Cash Flow | 22.60B | 45.45B | 50.73B | 49.54B | 48.89B | 44.64B |
Operating Cash Flow | 22.70B | 51.74B | 58.31B | 57.11B | 52.11B | 46.63B |
Investing Cash Flow | -16.11B | -39.15B | -39.46B | -21.93B | -23.41B | 3.59B |
Financing Cash Flow | -1.47B | -27.16B | 9.43B | -22.84B | -16.37B | -11.62B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥16.95B | 9.79 | 0.58% | -12.13% | 291.07% | ||
78 Outperform | $1.31T | 32.30 | 10.91% | 1.09% | 19.26% | -10.58% | |
76 Outperform | ¥126.09B | 20.29 | 1.98% | 12.93% | -14.83% | ||
75 Outperform | €105.41B | 46.27 | 12.05% | ― | 42.90% | -16.04% | |
68 Neutral | ¥254.57B | 42.69 | 0.41% | 28.85% | 26.67% | ||
64 Neutral | ¥343.76B | 10.59 | -2.88% | 2.57% | 11.81% | -7.17% | |
43 Neutral | ¥16.89B | 4,465.71 | 1.50% | -7.98% | -181.00% |
M3, Inc. has announced its relationship with its controlling shareholder, Sony Group Corporation, emphasizing its operational independence despite Sony’s significant ownership stake. The company maintains a policy of engaging in economically rational transactions with Sony, without exclusivity, ensuring autonomy in its business decisions.
The most recent analyst rating on (JP:2413) stock is a Buy with a Yen3300.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
M3, Inc. has announced the repurchase of its own common shares, with a total of 277,500 shares repurchased for 538,486,250 yen between May 3 and May 31, 2025. This move is part of a larger plan approved by the Board of Directors to repurchase up to 20 million shares, valued at a maximum of 20 billion yen, by April 30, 2026. The repurchase is conducted through open market purchases on the Tokyo Stock Exchange, and the company notes that the actual number of shares repurchased may vary based on market conditions.
The most recent analyst rating on (JP:2413) stock is a Buy with a Yen3300.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
M3, Inc. has announced a strategic decision to repurchase up to 20 million of its own shares, valued at a maximum of 20 billion yen, as part of its resource allocation strategy. This move is aimed at strengthening its resource base and preparing for new business development while responding to the Tokyo Stock Exchange’s call for management that is conscious of capital costs and stock price. The repurchase reflects M3’s commitment to shareholder returns and its focus on improving capital profitability indicators, including Return on Equity (ROE), especially as the impact of the COVID-19 pandemic on earnings has diminished.
M3, Inc. reported a significant decline in its non-consolidated financial results for the fiscal year ending March 31, 2025, compared to the previous year. The company experienced decreases in net sales and operating profit due to reduced pharmaceutical marketing budgets and the waning impact of COVID-19 projects. Additionally, ordinary profit and profit were further impacted by the absence of dividend income from subsidiaries, although this did not affect the consolidated financial results.
M3, Inc. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 19.3% increase in revenue to 284,900 million yen. Despite the revenue growth, the company experienced a decline in operating profit by 2.2% and profit attributable to owners of the parent by 10.6%. The financial results indicate challenges in maintaining profit margins despite increased revenue, which may impact stakeholder confidence and the company’s strategic positioning in the market.